Recent approaches to CD6 targeting therapies include itolizumab, a humanized anti-CD6 mAb in psoriasic patients (2, 48), in view to extend its use to rheumatoid arthritis (49) and Sjögren’s syndrome (50). The gene discussed is CD6; the disease is Sjogren syndrome.